Suketu Upadhyay Elected to Vertex Board of Directors
2022年5月18日 - 11:30PM
ビジネスワイヤ(英語)
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced that Suketu (“Suky”) Upadhyay has been elected to its
board of directors as an independent director. Mr. Upadhyay is a
global business executive with more than 20 years of experience in
the pharmaceutical and medical technology sectors, serving in
financial and strategy roles covering multiple areas of the life
sciences sector. He is currently the Executive Vice President and
Chief Financial Officer of Zimmer Biomet, a leading global
innovator and manufacturer of orthopedic solutions, a position he
has held since July 2019.
“We are delighted to have Suky join the Vertex Board. His
extensive financial and strategic experience in health care, paired
with his leadership and expertise across biopharma and medtech,
make him a valuable addition to our board of directors,” said
Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and
President.
“It’s an honor to join Vertex, a company focused on serial
innovation with an industry-leading track record of discovering,
developing and commercializing transformative medicines to treat
serious diseases. It is particularly exciting to join at such a
pivotal time, when the company is in the process of transforming
the treatment of multiple serious diseases, as it has done in
cystic fibrosis,” said Suky Upadhyay.
Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior
Vice President, Global Financial Operations at Bristol Myers Squibb
(BMS), where he was responsible for strategic and operational
initiatives across BMS’s supply chain, commercial operations,
R&D and business development. Prior to that, he served as
Executive Vice President and Chief Financial Officer of Endo
International and as an executive in various global finance and
strategy leadership roles at BD (Becton, Dickinson and Company)
including Interim Chief Financial Officer, Chief Accounting Officer
and CFO of International. In addition, Mr. Upadhyay has also held
several global finance and strategy roles at AstraZeneca and
Johnson & Johnson. Mr. Upadhyay holds a Bachelor of Science in
finance from Albright College and an MBA from The Fuqua School of
Business at Duke University.
The addition of Mr. Upadhyay brings Vertex’s board of directors
to 11 members, nine of whom are independent.
About Vertex
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious diseases. The company has multiple approved medicines
that treat the underlying cause of cystic fibrosis (CF) — a rare,
life-threatening genetic disease — and has several ongoing clinical
and research programs in CF. Beyond CF, Vertex has a robust
pipeline of investigational small molecule, cell and genetic
therapies in other serious diseases where it has deep insight into
causal human biology, including sickle cell disease, beta
thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes,
alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
Founded in 1989 in Cambridge, Mass., Vertex's global
headquarters is now located in Boston's Innovation District and its
international headquarters is in London. Additionally, the company
has research and development sites and commercial offices in North
America, Europe, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including 12 consecutive years on Science magazine's Top
Employers list and one of the 2021 Seramount (formerly Working
Mother Media) 100 Best Companies. For company updates and to learn
more about Vertex's history of innovation, visit www.vrtx.com or
follow us on Facebook, Twitter, LinkedIn, YouTube and
Instagram.
(VRTX-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005201/en/
Vertex Pharmaceuticals Incorporated Investors:
InvestorInfo@vrtx.com or 617-961-7163
Media: mediainfo@vrtx.com or 617-341-6992
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 6 2024 まで 7 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 7 2023 まで 7 2024